Key Takeaways

"Advanced cancer treatment in China" covers three distinct technologies, not one thing — proton/heavy-ion radiotherapy, immunotherapy, and targeted therapy. China's real edge is regulatory speed on specific drugs and a mature, lower-cost particle-therapy network — not a general claim of "better medicine."

The seven drugs driving this access gap have published trial results, not just approval — objective response rates ranging roughly 45–96% depending on the drug and cancer, in heavily pretreated patient populations (detailed in the table below).

Checkpoint-inhibitor efficacy appears broadly comparable between East Asian and non-East Asian patients in the best-studied cancer type (lung), though some targeted therapies do show real inter-ethnic differences — this is drug-specific, not something a general guide can promise either way.

Several partner-type hospitals hold JCI accreditation — the international division of The Joint Commission, the same body that accredits the majority of hospitals in the United States — though accreditation and physician credentials should always be verified directly before treatment.

Introduction

Most people who land on this search have heard some version of the same thing from an oncologist at home: standard treatment has been exhausted, or the next available option comes with real trade-offs, and it might be worth looking at what else exists. Somewhere in that research, "China" starts coming up — not as a single treatment, but as a place where several categories of newer cancer therapy are reportedly more accessible than they are elsewhere.

The problem is that "advanced cancer treatment" isn't one thing. It's a catch-all covering technologies that work in completely different ways, treat different cancers, and have nothing in common except being newer than standard chemotherapy and surgery. This guide exists to sort that out: what each category actually is, which cancers and situations each one is realistically relevant to, what it costs, what the actual trial data shows, and how to find out whether any of it applies to a specific case.

It's also worth naming the real alternative most readers in this position are weighing alongside China: Korea, Singapore, or staying home and pushing harder on standard options in the US, Canada, Australia, or New Zealand. China's specific edge isn't "better medicine" in the abstract — it's regulatory speed on a defined set of drugs and a mature, lower-cost particle-therapy network. Where China doesn't have that specific edge for a given diagnosis, it isn't the better choice, and this guide says so rather than defaulting to China regardless.

The Three Categories of Advanced Cancer Treatment in China

Proton and heavy-ion (carbon-ion) therapy is a form of radiation treatment. Instead of X-rays, it uses charged particles that can be aimed to release most of their energy directly inside a tumor, sparing more of the surrounding healthy tissue than conventional radiotherapy. It's most often discussed for tumors near critical structures — the brain, spine, or head and neck — and for pediatric cancers, where limiting radiation exposure to developing tissue matters.

Immunotherapy works differently: it doesn't attack the tumor directly, but changes how the immune system responds to it. Checkpoint inhibitors (the PD-1/PD-L1 and CTLA-4 class of drugs) block signals that cancer cells use to hide from immune attack. Newer bispecific antibodies target two of these signals with a single drug. Immunotherapy tends to be relevant for cancers with specific biomarkers — MSI-H/dMMR status, certain PD-L1 expression levels — rather than being broadly applicable across all cancer types.

Targeted therapy is a broader category that includes antibody-drug conjugates (ADCs) — antibodies that deliver a chemotherapy-like payload specifically to cancer cells expressing a particular marker, such as HER2 — and small-molecule drugs that block specific mutated proteins driving a cancer's growth. Like immunotherapy, targeted therapy only works if the tumor actually has the target the drug is designed for, which is why biomarker testing comes before any of this is a realistic option.

Proton and Heavy-Ion Therapy: One Pillar of Advanced Cancer Treatment in China

China now operates roughly a dozen proton and heavy-ion treatment centers currently listed as operational in the Particle Therapy Co-Operative Group's public facilities registry, with a further wave under construction. The most established is the Shanghai Proton and Heavy Ion Center (SPHIC), which opened in 2015 and has treated several thousand patients, publishing a flat, unchanged treatment-package price of approximately 310,000 RMB (roughly $45,000 USD) since opening. A 2022 peer-reviewed review of China's particle-therapy sector counted several operating facilities beyond Shanghai, including centers in Shandong and Guangdong, treating a combined total approaching 8,000 patients by that point and the network has expanded meaningfully since.

SPHIC's published price is the most concrete, independently reported figure available for a full proton or heavy-ion course; commonly cited US ranges for the equivalent treatment run $100,000–$200,000, more than double SPHIC's published rate. Pricing at other centers, and for more complex tumor sites requiring more sessions, should be confirmed directly with the specific hospital rather than assumed from SPHIC's figure — treatment typically runs 4–8 weeks depending on tumor location.

Proton and heavy-ion therapy is not a universal upgrade over standard radiation. It tends to be most clearly indicated for tumors close to sensitive structures, certain pediatric cancers, and select head, neck, and spinal tumors — a radiation oncologist's review of the specific tumor location is what determines whether it's actually the better option for a given case, not the technology's availability on its own.

Immunotherapy and Targeted Therapy: The Second Pillar of Advanced Cancer Treatment in China

This is the part of advanced cancer treatment in China that changes fastest, and it's worth understanding why. China's NMPA has used expedited review pathways — including priority review and conditional approval routes — to bring several cell and gene therapies and novel biologic drugs to market, in some cases years before the same drug clears full approval in the US or Europe. The result is a real, documented gap: several immunotherapy and targeted-therapy drugs are commercially available and NMPA-approved in China for specific indications — recurrent cervical cancer, HER2-expressing urothelial and gastric cancers, MSI-H/dMMR solid tumors, and certain lymphomas and leukemias among them — while the equivalent drug may still be in mid-stage clinical trials in a patient's home country.

This guide won't walk through each individual drug here, because that detail changes often enough that it deserves its own space, kept current on its own. For the current, specific list of NMPA-approved immunotherapy and targeted-therapy drugs available in China — including which cancers and biomarker profiles each one targets — see the companion guide to advanced therapies in China. Cellular therapies specifically (CD19 and BCMA CAR-T) are covered in more depth in our dedicated guide to CAR-T cell therapy cost in China.

What the Trial Data Actually Shows

"This technology exists" and "this technology works" are different claims, and it's fair to want the second one before weighing a trip. The seven drugs behind this access gap have published, peer-reviewed or conference-presented trial results — not just regulatory approval — and the numbers are worth seeing directly rather than taking on faith:

Therapy	Disease	Objective response rate	Other reported outcomes
Relmacabtagene autoleucel (CD19 CAR-T)	Relapsed/refractory mantle cell lymphoma	71.2%	59.3% complete response rate
Equecabtagene autoleucel (BCMA CAR-T)	Relapsed/refractory multiple myeloma	96.1%	78.8% progression-free at 12 months (n=103)
Zevorcabtagene autoleucel (BCMA CAR-T)	Relapsed/refractory multiple myeloma	92.2%	68.6% stringent complete response (n=102)
Disitamab vedotin (HER2 ADC)	HER2-positive advanced urothelial cancer	54.9%	Median overall survival 14.2–20.0 months
Cadonilimab (PD-1/CTLA-4 bispecific)	Recurrent/metastatic cervical cancer	57.8% (pooled, 10 studies, n=728)	62% 24-month overall survival rate
Envafolimab (subcutaneous PD-L1)	MSI-H/dMMR solid tumors, 2nd line+	42.7%	74.6% overall survival at 12 months
Lisaftoclax (BCL-2 inhibitor)	CLL/SLL after BTK inhibitor failure	62.5%	Median progression-free survival 23.9 months

A few things worth reading correctly in this table. These are objective response rates in the specific patient populations each trial enrolled — heavily pretreated patients who had already exhausted standard options, not a general cancer population — so they aren't directly comparable to first-line treatment statistics. An objective response rate also isn't a cure rate; it means the tumor measurably shrank or disappeared on imaging, which is a meaningful outcome but not the same as long-term survival, and durability varies by therapy (see the duration-of-response and progression-free survival figures where reported). These numbers describe how each drug performed in the trial population that led to its approval — not a guarantee of how it will perform for any individual patient, which depends on the case-specific factors covered in the next section.

How to Know Whether Advanced Cancer Treatment in China Applies to a Specific Case

Access to a therapy in China is not the same as suitability for it. Before any of the three categories above becomes a realistic option, the following typically has to be established:

• Diagnosis and histology — the precise subtype of the cancer, not just the general organ or tissue of origin

• Biomarker status — HER2 expression, MSI/dMMR status, PD-L1 expression, or the relevant target for whichever therapy is being considered, confirmed through current testing rather than assumed from an older pathology report

• Treatment history — which drugs or therapies have already been tried, and how the cancer responded to each

• Organ function and overall fitness — particularly relevant for immunotherapy (autoimmune risk) and particle therapy (ability to tolerate travel and a multi-week treatment course)

• Goals of care — whether the aim is curative treatment, disease control, or quality of life, since that shapes which options are worth pursuing at all

A therapy that could meaningfully help one patient may be irrelevant or unsafe for another with what looks like a similar diagnosis. This is why any serious look at advanced cancer treatment in China should start with a physician-led review of the actual medical record — not a general search for what's available.

Does Ethnicity Affect How These Therapies Work?

This is a fair question to ask directly, since these drugs were developed and largely trialed in Chinese patient populations. The honest answer is that it depends on the drug class, and the data on it is more reassuring for some categories than others.

For checkpoint inhibitors specifically, the largest body of comparative evidence comes from lung cancer research: multiple meta-analyses comparing East Asian and non-East Asian patients on PD-1/PD-L1 and CTLA-4 inhibitors have found broadly comparable response rates and survival outcomes between the groups, though one review noted a higher rate of immune-related side effects reported in Japanese patients specifically, a pattern not consistently seen across other Asian populations. That's reassuring for the immunotherapy and bispecific-antibody drugs covered here, though it isn't identical data — those studies were conducted in lung cancer, not necessarily the specific cancers each drug above is approved for.

Targeted therapies are a different story, and less uniformly reassuring: a review of tyrosine kinase inhibitor trials found real inter-ethnic differences in outcomes for some drugs — for example, certain EGFR-targeted therapies have shown better results in East Asian patients than non-Asian patients in head-to-head trial subgroups, while for at least one newer-generation drug the pattern reversed. This is exactly why biomarker and pharmacogenomic review matters more than category-level reassurance — the honest answer to "will this work the same for me" is drug-specific, not something a general guide can promise either way.

Where Advanced Cancer Treatment Happens in China

"China's top hospitals" is true but not a specific enough answer for a family trying to verify where they'd actually be going. Joint Commission International (JCI) accreditation — the international division of The Joint Commission, the same organization that accredits the majority of hospitals in the United States, using the same underlying quality and patient-safety standards — is held by a meaningful number of Chinese hospitals; a 2023 peer-reviewed study interviewing leadership at five JCI-accredited Chinese hospitals documented why hospitals pursue it and what changes as a result, evidence that the accreditation reflects a real operational shift, not just a marketing badge. China's major public academic cancer centers — the National Cancer Center in Beijing, Peking University Cancer Hospital, and Sun Yat-sen University Cancer Center among them — are the country's highest-volume specialist centers for the cancers discussed here and typically operate international/VIP departments for overseas patients, separately from JCI's private-hospital accreditation track.

Which specific hospital or hospitals are relevant to a given case depends on which therapy applies, and current accreditation status should always be verified directly against JCI's own public accreditation directory before treatment — hospital accreditation changes over time, and no article should be the final word on it.

How ChinaCureLink Helps With Advanced Cancer Treatment in China

Given how much the right option depends on details specific to one case, most of what's useful here happens before any treatment decision:

• Case review against all three categories at once. Rather than starting from "which technology sounds promising," your diagnosis, biomarkers, and treatment history are reviewed against what's actually available and appropriate — proton therapy, immunotherapy, targeted therapy, or none of the above.

• A direct answer, not a sales conversation. The purpose of the initial review is to tell you plainly whether a relevant option exists for your case — including telling you if it doesn't, rather than keeping the door open indefinitely.

• Hospital and specialist matching. Proton/heavy-ion centers, immunotherapy programs, and targeted-therapy prescribers aren't all at the same hospital — matching connects a case to the specific center equipped for the relevant therapy.

• Translation and documentation. Pathology reports, prior imaging, and treatment histories are translated and organized into the format Chinese specialists need for an efficient review.

• Ongoing coordination. For cases that proceed, the same team handles travel and visa logistics, and stays involved through treatment and follow-up rather than handing off after the initial match.

Submitting a case for review is a way to find out concretely what's realistic — it doesn't commit you to treatment in China.

What Patients Say About ChinaCureLink & Medebound HEALTH

China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.

Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot

Medebound HEALTH's online testimonials. Learn More

★★★★☆   Sarah Zhang  ·  Canada· Jul 2024  ·  Verified

“The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.”

★★★★★   Andrew Goh  ·  Singapore · Aug 2024  ·  Verified

“My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.”

Frequently Asked Questions

What counts as advanced cancer treatment in China?

In practice, three categories: proton and heavy-ion radiotherapy, immunotherapy (checkpoint inhibitors and bispecific antibodies), and targeted therapy (antibody-drug conjugates and small-molecule drugs). They work differently, treat different cancers, and aren't interchangeable.

How do I get started with advanced cancer treatment in China?

Through a case review that checks your diagnosis, biomarker status, and treatment history against what's actually available and appropriate — not by picking a technology first and asking whether you qualify for it.

Is proton therapy actually available in China, or is that overstated?

It's genuinely available and has been for over a decade — China operates roughly a dozen proton and heavy-ion centers currently listed as operational, the most established being the Shanghai Proton and Heavy Ion Center, open since 2015.

Why are some immunotherapy or targeted-therapy drugs available in China but not yet at home?

China's regulator has used expedited approval pathways for certain cell, gene, and biologic therapies, which has meant some drugs reach commercial approval in China years before the equivalent drug clears full approval elsewhere. This varies drug by drug and isn't universal.

How much does proton therapy cost in China compared to the US?

The Shanghai Proton and Heavy Ion Center publishes a flat package price of roughly $45,000 USD, versus commonly cited US ranges of $100,000–$200,000 for the same treatment — more than double SPHIC's rate. Pricing at other centers varies and should be confirmed directly.]

Does advanced cancer treatment in China actually work, or is it unproven?

The seven specific drugs discussed above have published trial results, not just regulatory approval — objective response rates ranging roughly 45–96% depending on the drug and cancer type, in patients who had already exhausted standard treatment. See the trial-data table above for the specific numbers behind each therapy.

Do I need to travel to China to find out if I'm a candidate?

No — initial case review is typically done remotely, based on medical records, pathology, and imaging submitted electronically. Travel becomes relevant only once a specific therapy and hospital have been identified as appropriate.

References

1. Particle Therapy Co-Operative Group (PTCOG) — Facilities in Clinical Operation. https://www.ptcog.site/index.php/facilities-in-operation-public

2. China's first hospital with heavy ion, proton radiotherapies sets new records for patients treated — Global Times, 2023. https://www.globaltimes.cn/page/202304/1289019.shtml

3. Li Y, Li X, Yang J, et al. Flourish of Proton and Carbon Ion Radiotherapy in China. Frontiers in Oncology, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882681/

4. China's NMPA Approves First CAR T-Cell Therapy for CLDN18.2+, HER2- Advanced Gastric/GEJ Adenocarcinoma — OncLive, 2026. https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma

5. Xie Y, Zhou K, Li L, et al. Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. Blood Advances, 2026. https://ashpublications.org/bloodadvances/article/10/4/1134/546727

6. Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy (citing equeca-cel comparator data). Experimental Hematology & Oncology, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12482220/

7. Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma. Experimental Hematology & Oncology, 2025. https://link.springer.com/article/10.1186/s40164-025-00710-y

8. Efficacy and Safety of Disitamab Vedotin in Patients With HER2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials. Journal of Clinical Oncology. https://ascopubs.org/doi/10.1200/JCO.22.02912

9. Efficacy and safety of Cadonilimab in the treatment of recurrent/metastatic and advanced cervical cancer: a systematic review and meta-analysis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12832733/

10. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. Journal of Hematology & Oncology, 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218452/

11. Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients with relapsed/refractory CLL/SLL who had failed BTK inhibitors. Blood (ASH Annual Meeting abstract), 2025. https://www.sciencedirect.com/science/article/pii/S0006497125026631

12. Peng L, et al. A meta-analysis on immune checkpoint inhibitor efficacy for advanced NSCLC between East Asians versus non-East Asians. Translational Lung Cancer Research, 2020. https://tlcr.amegroups.org/article/view/41958/html

13. Lee J, Sun JM, Lee SH, et al. Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? Journal of Thoracic Disease, 2020. https://pubmed.ncbi.nlm.nih.gov/32802459/

14. Inter-Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC12037692/

15. About Joint Commission International — Joint Commission. https://www.jointcommission.org/en-us/about-us/jci

16. Zhang H, Huang ST, Bittle MJ, et al. Perceptions of Chinese hospital leaders on Joint Commission International accreditation: a qualitative study. Frontiers in Public Health, 2023. https://pubmed.ncbi.nlm.nih.gov/37965503/

About ChinaCureLink

ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.

We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.

ChinaCureLink is proudly affiliated with Medebound HEALTH — an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia-Pacific, bringing the same standard of expert care coordination to every patient we serve.

This article is for informational purposes only and is not medical advice. Treatment suitability depends on individual diagnosis, biomarker status, and treatment history. Confirm all details with a patient coordinator and a treating oncologist before making any decisions.